SCODiA Report by MLBI Lab

Single-Cell Analysis of Breast Cancer: Unveiling Tumor Microenvironment Remodeling, Genomic Instability, and Therapeutic Vulnerabilities

This comprehensive single-cell RNA-seq analysis of human breast tissue delineates the cellular and molecular landscape of breast cancer, revealing striking differences between normal and primary tumor conditions. Malignant epithelial cells are characterized by extensive aneuploidy, profound cell cycle dysregulation, and metabolic reprogramming. The tumor microenvironment exhibits significant remodeling, with altered populations of pro-tumorigenic macrophages and T cell subsets, alongside widespread activation of cancer-associated fibroblasts. Critical cell-cell interaction networks and surfaceome markers are identified, highlighting key pathways driving tumor progression and offering promising therapeutic targets for precision medicine strategies.

Contents

  1. Dataset overview
  2. UMAP Visualization of Single-Cell RNA-seq Data in Breast Tissue
  3. Major Cell Type Score and Ploidy Distribution on UMAP Embedding
  4. Marker Expression Profile of Breast Tissue Cell Subsets
  5. Genomic Landscape of Epithelial Tumor Cells in Breast Cancer
  6. CNV-Informed UMAP Analysis of Breast Tissue Cells by Major Cell Type, Ploidy, Condition, and Sample
  7. Cell Type Population Analysis in Normal Breast Tissue vs. Primary Breast Tumor
  8. Analysis of T cell and Innate Lymphoid Cell Subsets in Breast Cancer
  9. Differential Abundance of T Cell Subsets in Breast Cancer
  10. Macrophage Subset Population Analysis in Breast Tissue
  11. Ploidy Analysis of Tumor-Origin Epithelial Cells in Breast Tissue
  12. Cell-Cell Interaction Patterns in Normal Breast Tissue vs. Primary Breast Tumor
  13. Differential Cell-Cell Interactions of Immune Checkpoint and Cell Cycle Pathways in Breast Cancer
  14. Condition-Specific Cell-Cell Interaction Patterns in Breast Cancer
  15. Epithelial Cell Condition-Specific Surfaceome Markers in Breast Tissue
  16. Macrophage Condition-Specific Surfaceome Marker Expression in Breast Cancer
  17. Fibroblast Condition-Specific Surfaceome Markers in Breast Cancer
  18. Dysregulation of Cell Cycle Pathway Genes in Primary Breast Tumor Epithelial Cells
  19. Gene Ontology (GSA) Analysis of Epithelial Cells in Breast Tissue Across Different Conditions
  20. Gene Set Enrichment Analysis (GSEA) Across Breast Tissue Cell Types in Primary Tumor vs. Normal Conditions
  21. Discussion
  22. Query List

0. Dataset overview

데이터셋 요약

1. UMAP Visualization of Single-Cell RNA-seq Data in Breast Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents UMAP (Uniform Manifold Approximation and Projection) visualizations of 88,707 single-cell RNA-seq profiles from breast tissue, colored by various annotations: condition (normal vs. primary_tumor), sample, celltype_major, celltype_minor, ploidy_dec (aneuploid vs. diploid), and celltype_subset. These visualizations are crucial for assessing dataset quality, identifying distinct cell populations, and understanding the overarching structure of the cellular landscape in the context of breast cancer.

Visual Summary

Condition

The UMAP colored by condition reveals a clear separation between normal (maroon) and primary_tumor (purple) cells. The primary_tumor cells predominantly occupy the large, interconnected clusters in the central and upper-right regions of the UMAP, forming the core of the embedding. normal cells, while present, are largely confined to distinct, smaller clusters, particularly a prominent, isolated cluster on the far left, and are less integrated into the main tumor-associated cell clusters. This strong segregation indicates substantial transcriptional differences between healthy and malignant tissue.

Sample

The sample UMAP shows a generally good intermixing of cells from different patient samples within the major clusters. This suggests that the data integration or embedding procedure has largely mitigated strong patient-specific batch effects, allowing for cross-sample comparisons. However, some smaller, more isolated clusters appear to be predominantly composed of cells from one or a few specific samples, which might indicate rare cell types or patient-specific biology that warrants further investigation.

Major Cell Type (celltype_major)

The celltype_major UMAP delineates distinct clusters corresponding to major cell types. Epithelial cell (orange) forms a large and prominent cluster, largely overlapping with the regions identified as primary_tumor in the condition UMAP. T cell (cyan) and Myeloid cell (light green) also form substantial, well-separated clusters, often in proximity to or partially intermingled with the epithelial cells, indicating their presence in the tumor microenvironment. Endothelial cell (red) and Stromal cell (light blue) occupy other distinct but smaller regions. B cell (dark red) and Mast cell (yellow) are present in more diffuse or smaller clusters. A distinct, isolated cluster on the far left is labeled unassigned (dark purple), consistent with the separated normal condition observed earlier.

Minor Cell Type (celltype_minor)

The celltype_minor UMAP provides a more granular view of cell identity. Within the broader Epithelial cell cluster, the individual Epithelial cell minor type still dominates. T cell CD4+ and T cell CD8+ show distinct sub-clustering within the T cell compartment. Macrophage (yellow) cells are a significant component of the myeloid compartment. Fibroblast (light orange) cells are clearly identifiable within the stromal clusters. The unassigned cluster (dark purple) remains distinct and isolated.

Ploidy Status (ploidy_dec)

The ploidy_dec UMAP shows a striking pattern: Aneuploid cells (maroon) are almost exclusively localized to the large, central, and interconnected clusters that largely represent Epithelial cell populations and primary_tumor conditions. Conversely, Diploid cells (light yellow) are broadly distributed, forming distinct clusters (including the unassigned cluster on the far left) and also populating regions alongside Aneuploid cells, likely representing non-malignant immune and stromal cells within the tumor microenvironment. This strong spatial correlation between aneuploidy, epithelial cells, and tumor condition is a critical observation.

Cell Type Subset (celltype_subset)

The celltype_subset UMAP offers the highest resolution of cell identities. This visualization highlights the considerable heterogeneity within the major and minor cell types. For instance, within the epithelial compartment, specific subsets like Luminal epithelial cell and Mammary epithelial cell are present. Various immune cell subsets, such as different T cell subtypes (e.g., T cell (Cytotoxic), T cell (Treg), T cell (Th1), T cell (Naive)) and macrophage polarizations (e.g., Macrophage (M1), Macrophage (M2A), Macrophage (M2B), Macrophage (M2C), Macrophage (M2D)), are resolved into distinct or partially overlapping regions. The unassigned cluster (dark purple) persists as a distinct entity, indicating a population yet to be fully characterized at this granular level.

Biological Interpretation

The UMAP visualizations provide compelling evidence for the cellular composition and disease-associated changes in breast tissue.

  1. Tumor Cell Identification: The strong co-localization of primary_tumor cells, Aneuploid cells, and Epithelial cell populations confirms the Epithelial cell as the primary tumor-origin cell type in this dataset, consistent with the inferred breast carcinoma context. This central Aneuploid Epithelial cell cluster represents the malignant compartment.
  2. Tumor Microenvironment (TME) Composition: The presence of distinct clusters for T cell, Myeloid cell, Stromal cell, and Endothelial cell within or adjacent to the Aneuploid Epithelial cell clusters underscores the complex cellular ecosystem of the tumor microenvironment. The diverse celltype_subset annotations further reveal the heterogeneity of immune cells, including various T cell and macrophage subtypes, which play critical roles in tumor progression and immune response.
  3. Normal Tissue Components: The normal condition cells form a more distinct and somewhat isolated cluster, primarily composed of Diploid cells and the unassigned cell population. This suggests that the healthy tissue components have a distinct transcriptional profile from the tumor-infiltrated regions. The unassigned cluster predominantly aligning with normal and Diploid cells indicates a population of non-malignant cells, possibly specialized normal breast epithelial cells or other healthy stromal/immune cells, that require further characterization.
  4. Cellular Heterogeneity in Cancer: The extensive granularity provided by celltype_subset highlights significant cellular heterogeneity, even within seemingly uniform major cell types. This is particularly relevant for the tumor, where various subtypes of epithelial cells and infiltrating immune cells can contribute differently to disease progression and treatment response.

Annotation Notes

2. Major Cell Type Score and Ploidy Distribution on UMAP Embedding

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the distribution of major cell type scores, ploidy status, and final major cell type assignments across a Uniform Manifold Approximation and Projection (UMAP) embedding of single-cell RNA-seq data from breast tissue. The HiCAT_major_score plots provide a quantitative measure of similarity to reference gene expression profiles for each major cell type, allowing for an assessment of cell identity and homogeneity. The ploidy_dec plot indicates whether cells are classified as Diploid, Aneuploid, or Unclear, which is particularly relevant in the context of breast cancer. The celltype_major plot shows the final annotated major cell types, providing a comprehensive overview of the cellular landscape.

Visual Summary

The UMAP embedding reveals distinct clusters corresponding to various cell populations.

Biological Interpretation

The UMAP plots provide crucial insights into the cellular composition and heterogeneity of the breast tissue, particularly in the context of breast cancer.

  1. Tumor Cell Identification: The data context inferred breast cancer with Epithelial cells as the "Resolved tumor-origin cell type" and 20.1% of cells being Aneuploid. The ploidy_dec plot strongly supports this inference, showing that the vast majority of aneuploid cells are co-localized within the large Epithelial cell cluster. This region, characterized by high HiCAT_major_score: Epithelial cell and annotated as Epithelial cell, represents the tumor cell population. The presence of aneuploidy is a hallmark of cancer, confirming the malignant nature of these epithelial cells PubMed search: aneuploidy cancer hallmark.
  2. Tumor Microenvironment (TME) Composition: The distinct clustering of various immune cells (T cells, B cells, Myeloid cells, Mast cells) and stromal cells (Fibroblasts, Smooth muscle cells, inferred from major type 'Stromal cell') around the epithelial/tumor cell compartment highlights the complex cellular landscape of the tumor microenvironment. These non-malignant cells play critical roles in tumor progression, immune surveillance, and therapeutic response PubMed search: tumor microenvironment cellular components.
  3. Cell Type Specificity and Annotation Quality: The strong concordance between the HiCAT_major_score for each cell type and their respective clusters in the celltype_major plot indicates high quality and confidence in the automated cell type annotation. Each score clearly delineates the expected cell populations, reinforcing the robustness of the clustering and labeling.
  4. Heterogeneity within Epithelial Cells: While a large fraction of epithelial cells are aneuploid, there appears to be a smaller population of diploid epithelial cells within the same cluster or adjacent to it. This suggests potential normal epithelial cells infiltrating or residing near the tumor, or perhaps different subclones within the tumor itself.
  5. Spatial Organization of Cells: The UMAP shows a clear functional segregation. The central and left regions are enriched with immune and stromal components (likely representing the tumor microenvironment and normal tissue components), while the upper-right is dominated by the tumor-origin epithelial cells.

Annotation Notes

3. Marker Expression Profile of Breast Tissue Cell Subsets

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a marker gene expression dot plot, visualizing the relative expression levels and prevalence of identified marker genes across different celltype_subset populations within the provided single-cell RNA-seq dataset. The dataset originates from human breast tissue, encompassing both 'primary_tumor' and 'normal' conditions, with a notable proportion of aneuploid cells and an identified epithelial tumor origin, suggesting a breast cancer context. The primary objective of this visualization, as per the interpretation priority, is to assess and validate the quality of the celltype_subset annotations based on the specificity and strength of marker gene expression patterns. The plot displays markers chosen to be highly specific for each cell group, favoring surfaceome genes, with a focus on distinguishing cell identities rather than differential expression between conditions.

Visual Summary

The dot plot effectively illustrates the expression of a curated set of marker genes across 22 distinct celltype_subset populations. Each row represents a celltype_subset, and each column represents a marker gene.

Overall, the visualization indicates robust and specific marker gene expression for most annotated celltype_subset populations, supporting the distinct identities of these cell types.

Biological Interpretation

The marker expression patterns observed in the dot plot provide strong biological evidence supporting the celltype_subset annotations within the human breast tissue context, consistent with general knowledge of immune, stromal, and epithelial cell populations, particularly in a tumor microenvironment.

The overall high specificity and robust expression of these markers across the various celltype_subset annotations strongly validate the bioinformatics pipeline's ability to accurately identify and classify these cell populations within the breast tissue microenvironment. The presence of these diverse cell types and their specific markers is characteristic of a complex tissue, especially in a tumor context where immune and stromal cell infiltration is common.

Annotation Notes

The dot plot provides compelling evidence that the celltype_subset annotations are well-supported by highly specific marker gene expression patterns. The clear diagonal blocks of enriched expression for distinct markers within each cell type strongly suggest that the assigned cell identities are robust and well-separated. The analysis successfully identified canonical markers for a wide range of immune, stromal, and epithelial cell populations, including specialized subsets like endothelial tip cells, lymphatic endothelial cells, and various T and B cell types, as well as distinct macrophage polarizations (M1, M2A, M2B, M2C). This high degree of marker specificity enhances confidence in the biological interpretations derived from these cell type assignments in downstream analyses, particularly when investigating cell-type-specific phenomena in the breast cancer context. No significant issues with overlapping or non-specific marker expression that would challenge current annotations were observed.

4. Genomic Landscape of Epithelial Tumor Cells in Breast Cancer

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates copy number variation (CNV) patterns specifically within epithelial cells from breast tissue, distinguishing between samples identified as "Patient" (likely tumor-derived due to aneuploidy) and "Diploid Patient" (likely normal-like or benign). The primary goal is to visualize the genomic alterations (amplifications and deletions) across samples and to summarize regions with significant copy number gains. This approach leverages single-cell RNA-seq data to provide a cell-type-specific view of genomic instability, focusing on the epithelial compartment which is the resolved tumor-origin cell type in breast cancer.

Visual Summary

CNV Heatmap (log2(CNR))

The heatmap displays log2(Copy Number Ratio, CNR) across genomic spots for individual samples, grouped by their presumed ploidy status. Red indicates genomic amplification (log2(CNR) > 0), while blue indicates genomic deletion (log2(CNR) < 0).

CNV Summary of Amplified Regions

The accompanying summary heatmap and bar chart detail the frequency and magnitude of recurrent amplifications across the "Patient_" samples.

Key Amplified Regions and Genes

Biological Interpretation

The analysis powerfully differentiates tumor-derived epithelial cells from likely normal or benign epithelial cells based on their genomic integrity. The "Patient_" samples, identified as aneuploid during initial data processing, exhibit a characteristic landscape of somatic copy number alterations, a hallmark of cancer. Conversely, the "Diploid Patient_" samples maintain a largely euploid genome, serving as an effective baseline.

The recurrent amplifications observed in the tumor-origin epithelial cells are highly relevant to breast cancer biology:

The cell-type-specific nature of this CNV analysis (focused on Epithelial cells) provides direct insight into the genomic alterations driving the cancer phenotype, given that epithelial cells are the origin of breast carcinoma.

Clinical or Translational Implications

The identified recurrent copy number amplifications in breast tumor epithelial cells have several important clinical implications:

Annotation Notes

The clear distinction in CNV patterns between "Patient_" and "Diploid Patient_" samples effectively validates the initial ploidy classification and the resolution of tumor-origin epithelial cells. The "Diploid Patient_" samples serve as a robust control, confirming the absence of significant genomic alterations in non-tumorigenic or benign epithelial cell populations. This strong agreement between observed CNV patterns and assigned ploidy/condition labels enhances confidence in the dataset annotations.

---

References

  1. EGFR in Breast Cancer:

PubMed search: "EGFR amplification breast cancer" - Review Article

  1. MYC in Breast Cancer:

GeneCards: MYC

PubMed search: "MYC amplification breast cancer" - Review Article

  1. CCND1 (Cyclin D1) in Breast Cancer:

GeneCards: CCND1

PubMed search: "CCND1 amplification breast cancer" - Review Article

  1. EGFR Inhibitors in Cancer:

PubMed search: "EGFR inhibitors cancer" - Review Article

5. CNV-Informed UMAP Analysis of Breast Tissue Cells by Major Cell Type, Ploidy, Condition, and Sample

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a series of Uniform Manifold Approximation and Projection (UMAP) plots, where the embedding was specifically generated using Copy Number Variation (CNV) information (cnv=True). This approach emphasizes transcriptional differences driven by underlying genomic aberrations. The UMAPs visualize the cellular landscape of breast tissue, colored by celltype_major, celltype_minor, ploidy_dec, condition (normal vs. primary_tumor), and sample. The goal is to understand the relationships between cell identity, genomic status (ploidy/CNV), and disease state within the context of a breast cancer dataset.

Visual Summary

The UMAP visualizations reveal distinct patterns influenced by the CNV-aware embedding:

Biological Interpretation

The CNV-informed UMAPs provide a powerful visualization of the cellular landscape in the context of breast cancer, integrating genomic and transcriptomic information.

  1. Tumor Cell Identification and Heterogeneity: The ploidy_dec and condition UMAPs strongly indicate that the primary_tumor condition is characterized by a significant population of Aneuploid cells. These Aneuploid cells largely correspond to Epithelial cells as seen in the celltype_major UMAP and as expected from the Resolved tumor-origin cell type: Epithelial cell in breast carcinoma. The distinct clustering of Aneuploid cells away from the main Diploid population, facilitated by the cnv=True embedding, underscores the profound genomic alterations in tumor cells.
    • The presence of multiple distinct Aneuploid clusters suggests intra-tumor heterogeneity at the genomic level, where different subclones of cancer cells may exist, each with unique CNV profiles. This is a common feature of advanced cancers and can have implications for treatment response and resistance 1.
    • Non-epithelial cells (e.g., immune cells, fibroblasts) within the primary_tumor condition are predominantly Diploid, as expected for non-malignant cells in the tumor microenvironment.
  2. Cell Type Segregation and Microenvironment: The major and minor cell type UMAPs show well-separated clusters for distinct cell lineages. This indicates that despite the CNV-driven embedding, fundamental cell identity markers remain a strong driver of transcriptional clustering, allowing for clear demarcation of immune, stromal, and endothelial compartments.
    • The close proximity or partial overlap of some Epithelial cells with Stromal and Myeloid cells in the main body of the UMAP could represent tumor-stroma interactions within the tumor microenvironment.
  3. Condition-Specific Cell Distribution: The condition UMAP clearly separates primary_tumor from normal cells, primarily driven by the Aneuploid vs. Diploid distinction. The normal tissue primarily consists of Diploid cells from various stromal and immune lineages, along with normal epithelial cells. The tumor samples, however, are characterized by the Aneuploid epithelial compartment alongside Diploid tumor-infiltrating immune cells and tumor-associated stromal cells.
  4. Sample-Level Variation: The sample UMAP reveals both shared features across samples and patient-specific genomic profiles. While many samples contribute to the general Diploid and Aneuploid clusters, certain smaller, distinct clusters, particularly within the Aneuploid populations, appear to be dominated by cells from individual patients. This highlights the genomic uniqueness of tumors even within the same cancer type, consistent with the diverse evolutionary paths of individual cancers 2.

Annotation Notes

The UMAPs provide strong support for the quality of the cell type annotations and ploidy assignments. The clear segregation of cell types, and especially the distinct clustering of Aneuploid cells largely corresponding to primary_tumor epithelial cells, suggests that the annotations are biologically meaningful and consistent with known cancer biology. The CNV-aware embedding successfully distinguishes cells based on their genomic integrity, which is a crucial aspect for studying cancer. The consistency between ploidy_dec, condition, and celltype_major (specifically Epithelial cell) further validates the accuracy of these annotations within the breast cancer context.

The minimal presence of Unclear ploidy cells further strengthens the reliability of the ploidy assignment.

References

[1] Navin N. Tumor heterogeneity in breast cancer. Genome Biol. 2015;16(1):235. doi: 10.1186/s13059-015-0809-5. PubMed search: Tumor heterogeneity breast cancer

[2] Burrell RA, Swanton V. Cancer evolution in the light of genomic instability. Cell. 2014;157(5):1013-1018. doi: 10.1016/j.cell.2014.04.053. PubMed search: Cancer evolution genomic instability

6. Cell Type Population Analysis in Normal Breast Tissue vs. Primary Breast Tumor

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a stacked bar plot visualizing the relative proportions of minor cell types across individual samples, distinguishing between 'normal' breast tissue and 'primary_tumor' conditions. Each bar represents a single sample, and the colored segments within each bar indicate the percentage contribution of different celltype_minor populations. This allows for a direct comparison of cellular composition shifts between healthy and cancerous breast tissue, as well as an assessment of heterogeneity within each condition.

Visual Summary

The bar plot clearly delineates distinct cellular landscapes between normal breast tissue and primary tumors.

Biological Interpretation

The observed shifts in cell type populations between normal and primary tumor conditions provide critical insights into the biological hallmarks of breast cancer.

The presence of a substantial "unassigned" fraction emphasizes the complexity and uniqueness of the cellular landscape within breast tumors, which can pose challenges for comprehensive cell type annotation.

Clinical or Translational Implications

Understanding the detailed cellular composition of breast tumors has several clinical and translational implications:

7. Analysis of T cell and Innate Lymphoid Cell Subsets in Breast Cancer

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the relative proportions of various T cell and Innate Lymphoid Cell (ILC) subsets within individual samples, distinguishing between normal breast tissue and primary breast tumor conditions. The data is derived from single-cell RNA sequencing of human breast tissue. The aim is to identify potential shifts in the immune cell composition within the tumor microenvironment compared to normal tissue, focusing on cell types crucial for adaptive and innate immunity.

Visual Summary

The visualization displays stacked bar plots for four normal samples and ten primary tumor samples. Each bar represents 100% of the combined T cell and ILC population within that sample, with different colors indicating specific subsets as defined in celltype_subset.

  1. Overall Composition: Both normal and primary tumor tissues harbor a diverse array of T cell and ILC subsets, including ILC1, ILC2, ILC3 (NCR+), ILC3 (NCR-), ILCreg, LTI, NK cell, and various T cell types such as T cell (Cytotoxic), T cell (Naive), T cell (Tfh), T cell (Th1), T cell (Th17), T cell (Th2), T cell (Th22), T cell (Th9), and T cell (Treg). An unassigned category is also present but represents a very small fraction.
  2. Differences between Normal and Tumor:
    • T cell (Cytotoxic) Enrichment: In most primary tumor samples, there is a visually apparent increase in the relative proportion of T cell (Cytotoxic) (light orange-yellow segment) compared to normal samples. This suggests a heightened presence of effector T cells.
    • T cell (Treg) Expansion: The proportion of T cell (Treg) (dark blue segment) appears notably higher in several primary tumor samples compared to normal tissue, indicating a potential increase in immunosuppressive cells.
    • T cell (Naive) Reduction: T cell (Naive) (lighter yellow segment) generally shows a decreased relative proportion in primary tumor samples. This may suggest differentiation or consumption of naive T cells within the tumor microenvironment.
    • Variability in Helper T cells and ILCs: While present, the individual proportions of helper T cell subsets (T cell (Th1), T cell (Th17), etc.) and ILCs (e.g., ILCreg, LTI, ILC3 (NCR-)) exhibit more heterogeneity across tumor samples and do not show a consistent pattern of enrichment or depletion as strong as the cytotoxic and regulatory T cells. NK cell proportions appear relatively stable or slightly reduced.
  3. Inter-sample Heterogeneity: There is greater variability in the relative immune cell composition among individual primary tumor samples compared to the normal samples, which show more consistent profiles.

Biological Interpretation

The observed shifts in T cell and ILC subset populations provide critical insights into the immune landscape of breast cancer.

  1. Active Anti-Tumor Response: The increased proportion of T cell (Cytotoxic) cells in primary tumors suggests an ongoing immune response attempting to eliminate cancer cells. Cytotoxic T lymphocytes (CTLs) are crucial for directly killing tumor cells presenting specific antigens.
  2. Immune Evasion and Suppression: Concurrently, the apparent expansion of T cell (Treg) populations in the tumor microenvironment (TME) is a hallmark of immune evasion in cancer. Tregs suppress effector immune cells, including cytotoxic T cells, thereby hindering effective anti-tumor immunity and promoting tumor progression. The balance between effector T cells and Tregs is a critical determinant of immune outcome.
  3. T Cell Activation and Differentiation: The reduction in T cell (Naive) cells in tumors implies that T cells are becoming activated and differentiating into various effector or regulatory phenotypes in response to tumor antigens or the inflammatory signals within the TME. This is a common feature of chronic immune stimulation.
  4. Complex TME Dynamics: The heterogeneity observed among tumor samples underscores the complex and patient-specific nature of immune infiltration and responses in breast cancer. Different patients may exhibit varying degrees of immune activation, suppression, or distinct immune cell recruitment patterns, influenced by tumor genetics, microenvironmental factors, and host immunity. While ILCs and NK cells also contribute to anti-tumor immunity or immune regulation, their consistent, dramatic shifts are less evident here compared to the T cell subsets.

Clinical or Translational Implications

The findings from this T cell and ILC subset analysis have several clinical implications relevant to breast cancer:

  1. Prognostic Biomarkers: The ratio of T cell (Cytotoxic) to T cell (Treg) (CTL:Treg ratio) is a well-established prognostic factor in various cancers, including breast cancer. A higher Treg proportion, as suggested in some tumor samples, is often associated with a poorer prognosis due to immunosuppression within the TME. PubMed search: CTL Treg ratio cancer prognosis
  2. Immunotherapy Strategy: The distinct immune profiles observed in primary tumors can inform patient stratification for immunotherapeutic interventions.
    • Checkpoint Blockade: Patients with a significant infiltration of T cell (Cytotoxic) cells, even if accompanied by Tregs, might be more responsive to immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 therapies) which aim to unleash these effector cells.
    • Targeting Tregs: Strategies to deplete or inhibit the function of T cell (Treg) could enhance anti-tumor immunity.
  3. Therapeutic Monitoring: Analyzing T cell subset dynamics can serve as a valuable tool for monitoring treatment response or disease progression, potentially allowing for adaptive therapeutic strategies.
  4. Understanding Immune Resistance: The variability in immune cell composition among individual patients highlights the need for personalized medicine approaches. Discrepancies in T cell (Cytotoxic) and T cell (Treg) balance may contribute to differential responses to standard and experimental therapies.

8. Differential Abundance of T Cell Subsets in Breast Cancer

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the relative proportions of specific T cell subset populations, as defined by celltype_subset, comparing primary breast tumor tissues to normal breast tissues. The box plots visualize the distribution of cell type proportions across individual samples for each condition, with statistical significance testing used to identify subsets showing differential abundance (p-value < 0.1). The analysis focuses on immune cell types broadly categorized under the T cell major cell type, including Th cell subsets and certain Innate Lymphoid Cells (ILCs) which are often grouped with T cells in immune profiling.

Visual Summary

The box plots illustrate statistically significant differences in the proportions of five immune cell subsets between primary tumor and normal conditions in breast tissue:

The black dots represent individual sample data points, showing the distribution and potential outliers.

Biological Interpretation

The observed shifts in T cell and ILC subset proportions within the breast tumor microenvironment provide critical insights into tumor immunology:

These findings collectively suggest an immune landscape in primary breast tumors that deviates significantly from normal tissue, characterized by an increased presence of T helper subsets often associated with pro-tumorigenic functions and a depletion of cells critical for organized anti-tumor immunity.

Clinical or Translational Implications

The distinct immune cell profiles in breast cancer tissues suggest several potential clinical implications:

9. Macrophage Subset Population Analysis in Breast Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a stacked bar plot visualizing the proportional distribution of various macrophage subsets (M1, M2A, M2B, M2C, M2D) across individual patient samples, stratified by 'normal' and 'primary_tumor' conditions. The data is derived from single-cell RNA sequencing of breast tissue, with an inferred biological context of Breast Cancer. The plot aims to highlight potential shifts in macrophage polarization within the tumor microenvironment compared to normal tissue.

Visual Summary

The visualization displays the relative abundance of five macrophage subsets (M1, M2A, M2B, M2C, M2D) in each sample.

Biological Interpretation

Macrophages are critical components of the tumor microenvironment (TME) and are often classified into M1 (pro-inflammatory, anti-tumor) and M2 (anti-inflammatory, pro-tumor) phenotypes, although this is a simplification of a more complex spectrum. The observed shift in macrophage populations between normal and primary tumor samples in breast tissue carries significant biological implications in the context of breast cancer:

This macrophage polarization towards an M2-like phenotype in the primary tumor microenvironment is a well-established mechanism by which tumors evade immune surveillance and promote their growth and spread. The specific enrichment of Macrophage (M2B) suggests distinct signaling pathways or cellular interactions are at play within the breast cancer TME.

Clinical or Translational Implications

The differential distribution of macrophage subsets between normal and tumor breast tissue has several potential clinical and translational implications:

Further research into the specific functions and molecular signatures of these macrophage subsets in breast cancer could lead to novel immunotherapeutic approaches.

References

  1. Tumor-Associated Macrophages in Cancer Progression and Therapy: https://pubmed.ncbi.nlm.nih.gov/?term=tumor+associated+macrophages+cancer+progression
  2. Macrophage Reprogramming in Cancer Immunotherapy: https://pubmed.ncbi.nlm.nih.gov/?term=macrophage+reprogramming+cancer+immunotherapy

10. Ploidy Analysis of Tumor-Origin Epithelial Cells in Breast Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the ploidy status (diploid, aneuploid, or unclear) within Epithelial cells identified as tumor-origin across various normal and primary_tumor samples from breast tissue. The purpose is to characterize chromosomal stability in healthy versus cancerous epithelial cell populations and to assess inter-sample variability within tumors.

Visual Summary

The visualization presents two bar plots, segmented by condition: 'normal' and 'primary_tumor'. Each bar represents a single patient sample, displaying the proportional distribution of ploidy populations (Aneuploid, Diploid, Unclear) within the Epithelial cells from that sample.

Biological Interpretation

The results clearly highlight a fundamental difference in genetic stability between normal and cancerous epithelial cells in the breast.

Clinical or Translational Implications

11. Cell-Cell Interaction Patterns in Normal Breast Tissue vs. Primary Breast Tumor

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interaction (CCI) patterns using CellPhoneDB, comparing normal breast tissue with primary breast tumor samples. The focus is on interactions involving key cell types: Epithelial cells (including diploid and aneuploid populations), Fibroblasts, Macrophages, and T cells (CD4+ and CD8+ subsets). The dot plots visualize the strength (mean expression) and significance (p-value) of ligand-receptor interactions between specified cell type pairs in both conditions.

Visual Summary

Normal Condition

The plot for normal tissue primarily displays interactions between Fibroblasts and Diploid Epithelial cells, as well as self-interactions within these populations.

Primary Tumor Condition

The plot for primary tumor tissue reveals a more complex and diverse interaction landscape, involving a wider array of cell types, including Macrophages and T cells, alongside Aneuploid Epithelial cells (identified as tumor cells).

Key Tumor-Specific Interactions:

Biological Interpretation

The observed CCI patterns provide critical insights into the shift from a homeostatic normal breast tissue to a pro-tumorigenic microenvironment in breast cancer.

Tumor Microenvironment Remodeling:

Clinical or Translational Implications

The distinct CCI profiles between normal and tumor conditions, especially the emergence of specific ligand-receptor pairs in the primary tumor, offer several clinical and translational opportunities:

Therapeutic Targeting:

12. Differential Cell-Cell Interactions of Immune Checkpoint and Cell Cycle Pathways in Breast Cancer

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interactions (CCI) involving genes associated with immune checkpoint and cell cycle pathways, comparing normal breast tissue with primary breast tumor tissue. The plot_cci_dots tool was used to visualize significant ligand-receptor interactions, with filtering applied to a predefined list of genes relevant to these pathways. The results highlight key intercellular communication changes in the tumor microenvironment.

Visual Summary

The provided dot plots illustrate cell-cell interactions for selected gene pairs in 'normal' and 'primary_tumor' conditions. The size of each dot represents the statistical significance (-log10(p-value)), and the color indicates the mean expression level of the interacting ligand-receptor pair (log2(mean)).

CCI in Normal Tissue

CCI in Primary Tumor Tissue

Enhanced TGF-beta Signaling in Tumor Microenvironment:

Biological Interpretation

The analysis reveals significant alterations in cell-cell communication networks in the primary breast tumor microenvironment, particularly concerning growth factor and cytokine signaling pathways known to influence cell cycle and immune responses.

  1. TGF-beta Pathway Dysregulation: The most prominent change is the increased and diversified activity of the Transforming Growth Factor-beta (TGF-beta) signaling pathway in the tumor. TGF-beta is a pleiotropic cytokine with complex roles in cancer, often acting as a tumor suppressor in early stages but promoting tumor progression, immune evasion, angiogenesis, and metastasis in advanced stages [1].
    • The strong interactions involving TGFB1/2 and their receptors between Aneuploid Epithelial cells, Fibroblasts, and Macrophages suggest a highly active TGF-beta axis within the tumor microenvironment. Fibroblasts (likely cancer-associated fibroblasts, CAFs) and Macrophages (tumor-associated macrophages, TAMs) are critical components of the tumor stromal compartment that often promote tumor growth and immune suppression via TGF-beta [2].
    • The TGFB1-integrin_avB6_complex interaction is notable as integrin αvβ6 is known to activate latent TGF-beta, further amplifying its signaling and contributing to tumor invasion and fibrosis [3]. Its prevalence in tumor-associated cell pairs suggests an environment conducive to increased TGF-beta activation.
  2. EGFR Signaling Reprogramming: Epidermal Growth Factor Receptor (EGFR) signaling is crucial for cell proliferation and survival, and its dysregulation is common in cancer. While active in normal tissue (especially involving ILCs), in the tumor, EGFR signaling interactions shift to involve Macrophages and Fibroblasts more prominently, interacting with Aneuploid Epithelial cells. This indicates a potential paracrine stimulation loop within the tumor microenvironment that could support tumor cell growth and survival.
  3. Cross-talk between Tumor Cells and Stroma/Immune Cells: The observed interactions underscore the critical cross-talk between the Aneuploid Epithelial cells (tumor cells), Fibroblasts, and Macrophages in shaping the tumor microenvironment. These interactions, driven by pathways like TGF-beta and EGFR, likely contribute to tumor proliferation, survival, immune evasion, and extracellular matrix remodeling—hallmarks of cancer.

Clinical or Translational Implications

The differential cell-cell interactions identified in this analysis point to several potential therapeutic targets and diagnostic opportunities in breast cancer:

  1. TGF-beta Pathway Inhibition: Given the significant upregulation and diversification of TGF-beta signaling, particularly involving Aneuploid Epithelial cells with stromal and immune components, targeting the TGF-beta pathway (e.g., TGF-beta receptor inhibitors, ligand traps, or integrin αvβ6 inhibitors) could be a promising therapeutic strategy to inhibit tumor growth, metastasis, and immune suppression in breast cancer [4, 5].
  2. EGFR Pathway Modulation: While EGFR inhibitors are established in some cancers, the specific cell-cell interaction patterns observed in breast cancer's tumor microenvironment might refine their application or suggest combination therapies. Targeting the specific ligand-receptor pairs (e.g., HBEGF-EGFR) between Macrophages and Aneuploid Epithelial cells could disrupt paracrine growth loops.
  3. Targeting the Tumor Microenvironment: The strong involvement of Fibroblasts and Macrophages in these altered interactions highlights the importance of targeting the tumor microenvironment, not just the tumor cells themselves. Modulating CAF and TAM functions, especially their contribution to TGF-beta and EGFR signaling, could enhance anti-tumor responses.

These findings provide a basis for prioritizing experimental validation studies focused on these pathways and cell populations to develop more effective treatments for breast cancer.

References

  1. Massagué, J. (2012). TGFβ in Cancer. *Cell*, 134(2), 215-230. PubMed Search: TGFb in Cancer
  2. Hinrichs, C.S., & Rosenberg, S.A. (2014). Exploiting the tumor microenvironment for the benefit of patients. *Seminars in Immunology*, 26(3), 253-262. PubMed Search: tumor microenvironment cancer
  3. Sheppard, D. (2015). Integrin αvβ6: a modulator of TGF-β activation in disease. *Journal of Clinical Investigation*, 125(11), 3763-3765. PubMed Search: integrin avB6 TGFB activation cancer
  4. Deng, Z., et al. (2020). TGF-β signaling in breast cancer and its therapeutic implications. *Frontiers in Oncology*, 10, 521921. PubMed Search: TGF-beta breast cancer therapy
  5. Arteaga, C.L., & Sledge, G.W. (2007). The EGF Receptor/HER2 Pathway in Cancer. *Clinical Cancer Research*, 13(24), 7247-7249. PubMed Search: EGFR HER2 cancer therapy

13. Condition-Specific Cell-Cell Interaction Patterns in Breast Cancer

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates condition-specific cell-cell interactions (CCI) involving major immune and stromal cells within breast tissue, comparing normal and primary_tumor conditions. The goal is to identify significantly different interactions, visualize them, and describe their biological and therapeutic relevance. The dot plot displays the scaled log strength of interactions (color intensity, where darker red indicates stronger interaction) and their statistical significance (-log10(p) value, indicated by dot size, where larger dots denote higher significance). Interactions were identified using a t-test with a p-value cutoff of 0.05. The analysis focused on Endothelial cells, B cells, Myeloid cells, Stromal cells, T cells, and Mast cells as target_cells.

Visual Summary

The dot plot provides a clear visual distinction between the cell-cell interaction landscape of normal and primary_tumor breast tissue samples.

The clear blue box delineates the normal and primary_tumor conditions, emphasizing the profound differences in their CCI profiles. The presence of strong and widespread interactions in the primary_tumor context strongly points to an active and complex tumor microenvironment (TME) crucial for cancer progression.

Biological Interpretation

The observed surge in cell-cell interactions within the primary_tumor microenvironment is a hallmark of breast cancer pathology, reflecting the intricate crosstalk between tumor cells, stromal cells (fibroblasts, smooth muscle cells), and endothelial cells that drives tumor growth, invasion, metastasis, and immune evasion.

Other Pro-tumorigenic Signaling:

The overall pattern indicates a highly reprogrammed TME in primary_tumor samples, characterized by active stromal-endothelial crosstalk that promotes angiogenesis, ECM remodeling, cell migration, and potentially immune modulation, all contributing to tumor progression.

Clinical or Translational Implications

The highly active cell-cell interactions identified in the primary_tumor context represent promising targets for therapeutic intervention in breast cancer. Disrupting these interactions could impede tumor growth, metastasis, and potentially enhance the efficacy of existing therapies.

  1. Integrin-Extracellular Matrix (ECM) Interactions (e.g., FN1-integrin_a5b1, COL6A1-integrin_a1b1)
    • Signaling Pathways and Mechanisms: Integrins are transmembrane receptors that link the ECM to the intracellular cytoskeleton, modulating cell adhesion, migration, proliferation, and survival. Upon binding to ECM components like fibronectin (FN1) or collagen (COL6A1), integrins activate various intracellular signaling pathways, including FAK (Focal Adhesion Kinase), Src, PI3K/Akt, and MAPK/ERK, which regulate gene expression, cell cycle progression, and resistance to apoptosis. In cancer, these interactions promote tumor cell invasion, metastasis, and chemoresistance by altering cell stiffness and mechanosensing.
    • Therapeutic Target Potential: Given their central role in ECM remodeling, tumor cell survival, and metastasis, targeting specific integrins or their ECM ligands could disrupt the structural and signaling support for tumor progression.

Relevant Therapeutic Agents:

  1. CXCL12-CXCR4 Axis (CXCL12-CXCR4--Fib|Endo)
    • Signaling Pathways and Mechanisms: CXCL12 binding to its G-protein coupled receptor, CXCR4, activates multiple downstream pathways, including PI3K/Akt, MAPK/ERK, and STAT3. These pathways are involved in cell proliferation, survival, migration, and angiogenesis. In the TME, CAFs produce CXCL12, recruiting CXCR4-expressing tumor cells, endothelial cells, and immunosuppressive immune cells, facilitating metastasis and creating an immune-suppressive environment.
    • Therapeutic Target Potential: Inhibiting the CXCL12-CXCR4 axis can block tumor cell migration, reduce metastasis, inhibit angiogenesis, and modulate the immune TME.

Relevant Therapeutic Agents:

  1. VEGFA-Neuropilin Signaling (VEGFA-NRP1/NRP2--Endo|Endo or Fib|Endo)
    • Signaling Pathways and Mechanisms: VEGFA primarily binds to VEGFRs (VEGF Receptors) on endothelial cells to stimulate angiogenesis. Neuropilin-1 (NRP1) and Neuropilin-2 (NRP2) are co-receptors that enhance VEGFA binding to VEGFRs and promote VEGFR signaling. This pathway is critical for endothelial cell proliferation, migration, and tube formation, leading to new blood vessel growth that supplies tumors with nutrients and oxygen.
    • Therapeutic Target Potential: Disruption of VEGFA-NRP1/NRP2 interactions can inhibit tumor angiogenesis, thereby starving the tumor and hindering its growth and metastasis.

Relevant Therapeutic Agents:

  1. FGF2-FGFR1 Axis (FGF2-FGFR1--Fib|SMC or Fib|Fib)
    • Signaling Pathways and Mechanisms: FGF2 (basic FGF) binds to Fibroblast Growth Factor Receptor 1 (FGFR1), a receptor tyrosine kinase. This interaction activates downstream signaling cascades, including MAPK/ERK, PI3K/Akt, and PLCγ, promoting cell proliferation, survival, migration, and angiogenesis. FGF2 can be secreted by various cells in the TME, including fibroblasts, and act on both stromal and endothelial cells.
    • Therapeutic Target Potential: Targeting FGFR1 can inhibit tumor cell proliferation, survival, and angiogenesis, particularly in tumors with FGFR1 amplification or aberrant activation.

Relevant Therapeutic Agents:

  1. PDGFB-PDGFRB Axis (PDGFB-PDGFRB--Endo|Fib)
    • Signaling Pathways and Mechanisms: PDGFB (Platelet-Derived Growth Factor B) binds to PDGFRB (Platelet-Derived Growth Factor Receptor beta), a receptor tyrosine kinase. Activation of PDGFRB signals through pathways like PI3K/Akt and MAPK/ERK, promoting proliferation, migration, and survival of stromal cells (fibroblasts, pericytes, smooth muscle cells) and endothelial cells. This axis is crucial for recruitment of pericytes to stabilize new blood vessels, and for fibroblast activation and fibrosis in the TME.
    • Therapeutic Target Potential: Inhibiting PDGFRB can reduce stromal support for tumors, normalize tumor vasculature, and decrease desmoplasia, potentially improving drug delivery.

Relevant Therapeutic Agents:

  1. GAS6-AXL Signaling (GAS6-AXL--Fib|Endo)
    • Signaling Pathways and Mechanisms: Growth Arrest-Specific 6 (GAS6) is a ligand for the AXL receptor tyrosine kinase. Upon binding, AXL activates PI3K/Akt and MAPK/ERK pathways, leading to increased cell survival, proliferation, migration, and invasion. The GAS6-AXL pathway is frequently overactivated in aggressive breast cancers and contributes to resistance to chemotherapy, radiation, and targeted therapies [4]. It also plays a role in regulating immune responses.
    • Therapeutic Target Potential: Targeting AXL could overcome resistance to current therapies, reduce metastasis, and modulate the immune TME in breast cancer.

Relevant Therapeutic Agents:

These findings underscore the complex, interconnected nature of the breast cancer microenvironment and provide a rationale for exploring targeted therapies that disrupt specific pro-tumorigenic cell-cell interactions.

References

  1. Lu, P., et al. (2012). The extracellular matrix: a dynamic niche for cancer progression. *Journal of Cell Biology*, 196(4), 395-405. PubMed search: "extracellular matrix cancer progression"
  2. Paszek, M. J., et al. (2005). Allosteric regulation of integrin-ligand binding by cell-generated tension. *Nature*, 436(7051), 546-550. PubMed search: "integrin cancer stiffness"
  3. Raz, Y., et al. (2014). The CXCR4-CXCL12 axis in cancer. *Cell and Tissue Research*, 355(3), 513-524. GeneCards: CXCR4
  4. Rankin, E. B., et al. (2016). The GAS6-AXL signaling pathway in cancer progression and therapy response. *Cancers (Basel)*, 8(11), 93. UniProt: AXL
  5. Yamamoto, H., et al. (2017). SFRP2: a multi-functional molecule involved in various biological processes including inflammation, cancer, and tissue repair. *Biochimica et Biophysica Acta (BBA)-Reviews on Cancer*, 1867(1), 108-115. PubMed search: "SFRP2 cancer Wnt"
  6. Wey, J. S., et al. (2005). Neuropilins: emerging targets in cancer therapy. *Clinical Cancer Research*, 11(3), 779-787. GeneCards: NRP1
  7. Dienstmann, R., et al. (2017). FGFR: a druggable target in cancer. *Cancer Treatment Reviews*, 55, 1-13. UniProt: FGFR1
  8. Tanaka, M., et al. (2020). Targeting AXL for cancer therapy. *Cancers (Basel)*, 12(1), 168. PubMed search: "AXL inhibitor breast cancer"

14. Epithelial Cell Condition-Specific Surfaceome Markers in Breast Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a dot plot visualization of surfaceome marker gene expression in Epithelial cells across different samples and conditions (normal vs. primary_tumor). The goal was to identify condition-specific markers, particularly focusing on those expressed in primary tumor epithelial cells, and to distinguish between established therapeutic targets and potential novel targets. The visualization displays the mean expression level (color intensity) and the fraction of cells expressing the gene (dot size) for selected surfaceome genes in Epithelial cells, grouped by sample and overall condition.

Visual Summary

The dot plot is organized into two main sections along the x-axis: 'normal' and 'primary_tumor' conditions. Samples are listed on the y-axis, further categorized by their inferred ploidy status, with 'Diploid Patient' samples under 'normal' and 'Patient' samples under 'primary_tumor'. This arrangement effectively separates normal epithelial cells from tumor-associated epithelial cells.

Key observations from the plot:

Biological Interpretation

The differential expression of surfaceome markers between normal and primary tumor epithelial cells provides crucial insights into the molecular changes occurring during breast cancer progression. Surface proteins are particularly important as they mediate cell-cell and cell-extracellular matrix interactions, signal transduction, and are directly accessible for therapeutic targeting.

Markers Highly Expressed in Normal Epithelial Cells

Many genes expressed in normal epithelial cells, such as those related to cell adhesion (e.g., ITGA2, FAT1, CRB3, ALCAM), ion transport (e.g., SLC family genes), and general epithelial function, represent the baseline molecular machinery for maintaining tissue homeostasis. Their consistent expression in normal samples, and downregulation or absence in tumor samples, highlights a potential loss of normal epithelial characteristics in cancer.

Markers Highly Expressed in Primary Tumor Epithelial Cells

The genes predominantly expressed in primary tumor epithelial cells are of significant biological and clinical interest, as they likely drive or are associated with cancerous phenotypes.

Clinical or Translational Implications

The identification of condition-specific surfaceome markers in primary tumor epithelial cells holds significant clinical and translational value for breast cancer.

Established Therapeutic Targets

Less Well-Characterized Markers with Potential as Therapeutic Targets

The distinct expression profiles highlight a panel of surfaceome markers that could serve as diagnostic biomarkers, prognostic indicators, or targets for novel therapeutic interventions in breast cancer. Further functional validation in cellular and in vivo models, alongside clinical correlation studies, would be crucial to advance these findings towards clinical application.

15. Macrophage Condition-Specific Surfaceome Marker Expression in Breast Cancer

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies condition-specific surfaceome markers in Macrophage cells from breast tissue, comparing normal samples against primary tumor samples. The dot plot visualizes the mean expression level and the fraction of cells expressing each marker across various patients. The goal is to highlight markers that are differentially expressed between normal and tumor microenvironments, focusing on their biological relevance, potential as therapeutic targets, and associated signaling pathways within the context of breast cancer.

Visual Summary

The dot plot displays the expression of 40 surfaceome markers in Macrophage cells across multiple patients, categorized by 'normal' and 'primary_tumor' conditions. Each row represents a patient, and each column corresponds to a specific marker. The size of the dot indicates the fraction of cells expressing the marker within that patient's Macrophage population, while the color intensity (from light to dark red) represents the mean expression level.

Key Observations:

Biological Interpretation

Macrophages are critical components of the tumor microenvironment (TME), playing diverse roles that can either promote or inhibit tumor progression. The differential expression of surfaceome markers in tumor-associated macrophages (TAMs) compared to normal macrophages indicates a phenotypic shift influenced by the TME.

Macrophage Markers Enriched in Primary Tumor

Markers showing upregulation in tumor-associated macrophages often reflect their adaptation to the tumor microenvironment, contributing to angiogenesis, immune suppression, metastasis, and therapy resistance.

  1. IL6R (Interleukin-6 Receptor, CD126):
    • Signaling Pathways: IL6R binds IL-6, activating the JAK-STAT3 pathway. This pathway is crucial for cell proliferation, survival, differentiation, and inflammation. In the TME, IL-6/JAK-STAT3 signaling in TAMs can promote an immunosuppressive phenotype and contribute to tumor growth and metastasis PubMed Search: IL6R STAT3 tumor macrophages.
    • Role in TME: Upregulated IL6R on TAMs enhances their responsiveness to tumor-derived IL-6, leading to the polarization towards pro-tumorigenic M2-like phenotypes, increased angiogenesis, and suppression of anti-tumor immunity.
    • Therapeutic Target Potential: High IL6R expression makes it an attractive therapeutic target. Blocking IL-6/IL6R signaling could reprogram TAMs towards an anti-tumor phenotype or inhibit their pro-tumor functions.
    • Relevant Therapeutic Agents: Tocilizumab and sarilumab are anti-IL-6R antibodies approved for inflammatory diseases; their potential in cancer, particularly in targeting TAMs, is under investigation PubMed Search: anti-IL6R antibody cancer clinical trials.
  2. CXCR4 (C-X-C Chemokine Receptor Type 4):
    • Signaling Pathways: CXCR4 binds to its ligand CXCL12 (SDF-1α), activating G-protein coupled receptor (GPCR) signaling, leading to downstream activation of MAPK, PI3K/Akt, and JAK/STAT pathways. These pathways regulate cell migration, proliferation, and survival GeneCards: CXCR4.
    • Role in TME: CXCR4 is vital for the recruitment of macrophages to the tumor site, drawn by CXCL12 secreted by tumor cells and stromal cells. Once in the TME, CXCR4 signaling can promote TAM survival, differentiation, and their pro-tumorigenic functions, including angiogenesis and metastasis.
    • Therapeutic Target Potential: Targeting the CXCL12-CXCR4 axis can inhibit TAM recruitment and metastatic dissemination.
    • Relevant Therapeutic Agents: Plerixafor (AMD3100) is an FDA-approved CXCR4 antagonist used in stem cell mobilization. Other CXCR4 antagonists are in clinical development for various cancers PubMed Search: CXCR4 antagonist cancer therapy.
  3. MET (MET Proto-Oncogene, Receptor Tyrosine Kinase):
    • Signaling Pathways: MET is activated by its ligand HGF (Hepatocyte Growth Factor). HGF binding induces MET dimerization and autophosphorylation, activating downstream signaling pathways such as RAS-MAPK, PI3K-AKT, and STAT3, which are crucial for cell proliferation, survival, migration, and invasion UniProt: P08581 (MET_HUMAN).
    • Role in TME: MET signaling in TAMs can contribute to their survival, motility, and differentiation into pro-tumorigenic phenotypes. It also plays a role in fostering an immunosuppressive environment and promoting tumor angiogenesis.
    • Therapeutic Target Potential: MET is a well-established oncogene in many cancers. Its expression on TAMs suggests that MET inhibitors could not only target tumor cells but also modulate the pro-tumorigenic functions of TAMs, making it a dual-target strategy.
    • Relevant Therapeutic Agents: Several MET inhibitors (e.g., crizotinib, capmatinib, tepotinib) are approved for specific MET-driven cancers or are in clinical trials.
  4. ITGAV (Integrin Alpha-V, CD51) and ITGB2 (Integrin Beta-2, CD18):
    • Signaling Pathways: Integrins are heterodimeric cell surface receptors that mediate cell-extracellular matrix (ECM) and cell-cell interactions. Upon ligand binding, they activate focal adhesion kinase (FAK), Src kinases, and other signaling molecules, influencing cell adhesion, migration, proliferation, and survival GeneCards: ITGAV. ITGAV often pairs with various beta subunits (e.g., ITGB3, ITGB5, ITGB6) to recognize ligands like vitronectin and fibronectin. ITGB2 pairs with ITGAL (CD11a), ITGAM (CD11b), ITGAX (CD11c), or ITGAD (CD11d) to form leukocyte-specific integrins (e.g., LFA-1, Mac-1, CR4).
    • Role in TME: Integrins on TAMs are critical for their adhesion to endothelial cells (diapedesis), migration within the TME, and interaction with the ECM and tumor cells. This facilitates TAM recruitment, retention, and pro-tumorigenic functions. ITGB2-containing integrins (e.g., Mac-1) are crucial for macrophage adhesion, phagocytosis, and inflammatory responses.
    • Therapeutic Target Potential: Blocking specific integrins could impede TAM infiltration into tumors, reduce their interaction with tumor cells, and inhibit their pro-tumor functions.
    • Relevant Therapeutic Agents: Integrin antagonists (e.g., cilengitide targeting αvβ3/αvβ5 integrins) have been explored in cancer therapy to inhibit angiogenesis and metastasis.

Macrophage Markers Enriched in Normal Condition

Markers highly expressed in macrophages from normal tissue typically reflect their roles in tissue homeostasis, immune surveillance, and resolution of inflammation.

  1. CD163 (Scavenger Receptor Cysteine-Rich Type 1 Protein M130):
    • Signaling Pathways: CD163 is a scavenger receptor primarily involved in the clearance of hemoglobin-haptoglobin complexes. Ligation can activate signaling pathways like MAPKs and PI3K/Akt, influencing anti-inflammatory and immunosuppressive responses GeneCards: CD163.
    • Role in TME: CD163 is a well-known marker for M2-polarized macrophages, often associated with immune suppression, tissue remodeling, and angiogenesis. Its relatively higher expression in normal macrophages compared to tumor macrophages in some patients here might indicate a baseline homeostatic or early M2-like phenotype, which might be further enhanced or shifted in the tumor. However, in many cancers, TAMs in the tumor also express high levels of CD163. The pattern here suggests a more uniform expression in normal for certain patients.
    • Therapeutic Target Potential: While often a marker of pro-tumorigenic TAMs, its prevalence in normal tissue macrophages limits direct targeting without broad off-target effects. However, understanding its regulation could inform strategies to re-polarize TAMs.
    • Relevant Therapeutic Agents: No direct therapeutic agents targeting CD163 are widely used in cancer, but its expression is often used as a prognostic marker.
  2. MSR1 (Macrophage Scavenger Receptor 1, CD204):
    • Signaling Pathways: MSR1 is a pattern recognition receptor involved in endocytosis of modified low-density lipoproteins (LDL) and pathogens. Its signaling can influence phagocytosis, inflammation, and lipid metabolism UniProt: P21757 (MSR1_HUMAN).
    • Role in TME: MSR1 is another marker associated with M2-like macrophages. Its presence in normal macrophages points to their role in debris clearance and tissue maintenance. In the TME, MSR1 can contribute to pro-tumorigenic functions by enhancing lipid uptake, which supports tumor cell growth and immunosuppression.
    • Therapeutic Target Potential: Similar to CD163, MSR1 is also expressed by diverse macrophage populations. Strategies might focus on modulating its function rather than direct depletion.
    • Relevant Therapeutic Agents: No specific therapeutic agents directly targeting MSR1 for cancer are currently in widespread clinical use.

Clinical or Translational Implications

The identification of surfaceome markers specifically enriched on Macrophages within the primary breast tumor microenvironment provides critical insights for therapeutic development:

16. Fibroblast Condition-Specific Surfaceome Markers in Breast Cancer

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes surfaceome markers differentially expressed in Fibroblast cells from 'normal' versus 'primary_tumor' breast tissue conditions. The dot plot displays the mean expression level (color intensity) and the fraction of cells expressing each marker (dot size) across individual patient samples, grouped by condition. The analysis specifically focuses on surfaceome markers, which are particularly relevant for therapeutic targeting.

Visual Summary

The dot plot clearly delineates two distinct expression patterns for Fibroblast cells, corresponding to the 'normal' and 'primary_tumor' conditions.

The stark contrast in marker expression underscores a significant transcriptional reprogramming of fibroblasts in the breast tumor microenvironment (TME), leading to the emergence of specialized cancer-associated fibroblasts (CAFs).

Biological Interpretation

The observed differential expression patterns highlight the profound changes fibroblasts undergo in the presence of breast cancer, transforming into CAFs that actively support tumor progression. The identified surfaceome markers provide insights into CAF functions and represent potential targets for therapeutic intervention.

Markers Enriched in Normal Fibroblasts

These markers characterize fibroblasts in their homeostatic state, prior to tumor-induced activation. Their downregulation in the tumor setting suggests a loss of normal fibroblast identity or suppression of their baseline functions.

Markers Enriched in Cancer-Associated Fibroblasts (CAFs)

The upregulation of these surfaceome markers reflects the activated, pro-tumorigenic phenotype of CAFs, which are critical components of the breast cancer tumor microenvironment (TME). These markers are crucial for understanding CAF biology and offer significant potential for targeted therapies.

Key CAF Markers with High Therapeutic Relevance:

  1. FAP (Fibroblast Activation Protein alpha):
    • Signaling Pathways: Functions as a serine protease that cleaves specific components of the extracellular matrix (ECM), contributing to ECM remodeling. It can also degrade certain chemokines, influencing immune cell infiltration.
    • Role in TME: FAP is a widely recognized hallmark of activated CAFs in various cancers, including breast cancer. FAP-positive CAFs promote tumor growth, invasion, metastasis, and angiogenesis. They also foster an immunosuppressive microenvironment by recruiting myeloid-derived suppressor cells and inhibiting T cell function, contributing significantly to desmoplasia.
    • Therapeutic Target Potential: High, due to its ubiquitous expression in CAFs across different tumor types and minimal expression in normal adult tissues.
    • Relevant Therapeutic Agents: FAP-targeting strategies include monoclonal antibodies, small molecule inhibitors (e.g., talabostat), FAP-targeted CAR-T cell therapies, and FAP-targeted radionuclide therapies (e.g., FAP-2286) for diagnostic imaging and targeted delivery of cytotoxic agents. PubMed Search: FAP breast cancer therapy
  2. MMP14 (Matrix Metallopeptidase 14 / MT1-MMP):
    • Signaling Pathways: A membrane-anchored matrix metalloproteinase that directly degrades various ECM components (e.g., collagens, fibronectin) and activates other MMPs. This activity facilitates cell migration and invasion.
    • Role in TME: Upregulated in CAFs and tumor cells, MMP14 is a critical driver of ECM degradation, creating pathways for tumor cell invasion and metastasis. It also promotes angiogenesis by modifying the ECM and releasing pro-angiogenic factors.
    • Therapeutic Target Potential: High, given its central role in invasion and metastasis.
    • Relevant Therapeutic Agents: While broad-spectrum MMP inhibitors faced challenges with toxicity, more specific MMP14 inhibitors are being developed to disrupt tumor progression and metastatic dissemination. GeneCards: MMP14
  3. AXL (AXL Receptor Tyrosine Kinase):
    • Signaling Pathways: Activated by its ligand GAS6, AXL triggers intracellular signaling cascades including PI3K/Akt, MAPK/ERK, and STAT pathways, promoting cell proliferation, survival, migration, and drug resistance.
    • Role in TME: Overexpressed in aggressive cancers and often in CAFs, AXL drives tumor progression, metastasis (particularly via epithelial-mesenchymal transition, EMT), immune evasion, and resistance to chemotherapy and targeted therapies. In CAFs, AXL contributes to their activation and interactions with tumor cells.
    • Therapeutic Target Potential: High, as it is a key driver of aggressive disease and therapy resistance.
    • Relevant Therapeutic Agents: Several AXL inhibitors (e.g., bemcentinib, gilteritinib, cabozantinib) are in clinical trials for various cancers, including breast cancer, often in combination with other anti-cancer agents. PubMed Search: AXL inhibitor breast cancer
  4. NRP1 (Neuropilin 1):
    • Signaling Pathways: Functions as a co-receptor for diverse ligands, including VEGF-A (involved in angiogenesis) and Class 3 Semaphorins (involved in neuronal guidance and immune regulation). It modulates their signaling by enhancing ligand binding to primary receptors (e.g., VEGFR2) or by forming independent signaling complexes.
    • Role in TME: Promotes tumor angiogenesis, growth, and metastasis. In CAFs, NRP1 can enhance pro-angiogenic signaling and contribute to immune suppression. It also mediates interactions between CAFs and other TME components like tumor cells or endothelial cells.
    • Therapeutic Target Potential: Significant, due to its involvement in multiple pro-tumorigenic processes.
    • Relevant Therapeutic Agents: Antibodies targeting NRP1 are under investigation, aiming to block its ability to promote angiogenesis and tumor progression. GeneCards: NRP1
  5. GPNMB (Glycoprotein NMB):
    • Signaling Pathways: A transmembrane glycoprotein involved in cell adhesion, motility, and proliferation. It can activate downstream pathways like PI3K/Akt and ERK, promoting cell growth and survival.
    • Role in TME: Associated with aggressive tumor phenotypes, metastasis, and therapy resistance in various cancers, including triple-negative breast cancer. Expressed by both tumor cells and CAFs, it contributes to immune suppression and tissue remodeling.
    • Therapeutic Target Potential: Promising, particularly for targeted drug delivery.
    • Relevant Therapeutic Agents: Antibody-drug conjugates (ADCs) such as glembatumumab vedotin (targeting GPNMB) have been investigated in breast cancer. GeneCards: GPNMB
  6. CDH11 (Cadherin 11 / OB-cadherin):
    • Signaling Pathways: A classical cadherin that mediates calcium-dependent homophilic cell-cell adhesion. It links to the actin cytoskeleton via catenins, influencing cell motility and tissue architecture. Can also interact with Wnt signaling components.
    • Role in TME: Upregulated in CAFs and some tumor cells, CDH11 promotes CAF activation, contributes to collective cell migration, and enhances tumor cell invasion and metastasis by facilitating crucial tumor-stroma interactions.
    • Therapeutic Target Potential: Emerging. Targeting CDH11 could disrupt CAF-tumor cell interactions and inhibit metastatic processes.
    • Relevant Therapeutic Agents: Monoclonal antibodies targeting CDH11 are under preclinical investigation. GeneCards: CDH11
  7. ANTXR1 (Anthrax Toxin Receptor 1 / TEM8):
    • Signaling Pathways: Primarily known as a receptor for anthrax toxin, ANTXR1 also plays a physiological role in angiogenesis. It interacts with ECM proteins and is involved in endothelial cell migration and tube formation.
    • Role in TME: Highly expressed in tumor vasculature and some stromal cells, promoting tumor angiogenesis and growth. It is considered a tumor endothelial marker and is also expressed by certain CAF subsets.
    • Therapeutic Target Potential: Significant, especially for anti-angiogenic strategies and targeted drug delivery to the tumor vasculature and stroma.
    • Relevant Therapeutic Agents: ANTXR1-targeting ADCs and immunotoxins are being investigated to specifically deliver cytotoxic agents to tumor blood vessels and CAFs. GeneCards: ANTXR1

Other Significant CAF Markers:

Clinical or Translational Implications

The identification of these surfaceome markers on CAFs in breast cancer has several important clinical and translational implications:

Overall, this analysis provides a valuable molecular map of fibroblast transformation in breast cancer, pinpointing specific surface targets that could be exploited for novel diagnostic and therapeutic approaches to combat this disease.

17. Dysregulation of Cell Cycle Pathway Genes in Primary Breast Tumor Epithelial Cells

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the differential expression of a curated set of cell cycle pathway genes in Epithelial cells from primary breast tumors compared to normal breast tissue. Using single-cell RNA-seq data, the "expressing cell fraction (sample)" for each gene was compared between the primary_tumor and normal conditions, and statistically significant differences were identified. The Epithelial cell type was selected as the target, given its identification as the tumor-origin cell type in breast cancer. The objective was to highlight genes with altered prevalence of expression within epithelial cell populations, which could indicate shifts in cell cycle activity or regulatory mechanisms in the tumor microenvironment.

Visual Summary

The box plots display the expressing cell fraction (sample) for 16 key cell cycle-related genes across primary tumor and normal conditions. Each black dot represents a sample.

Overall, a predominant pattern emerges where many key cell cycle regulators exhibit a significantly higher fraction of expressing cells within the primary tumor epithelial population.

Biological Interpretation

The observed patterns of gene expression indicate a profound dysregulation of cell cycle control within the epithelial cells of primary breast tumors, consistent with their malignant transformation and proliferative phenotype.

  1. Increased Proliferative Signaling and DNA Replication Machinery:
    • The significant upregulation of genes like WEE1, E2F3, TFDP2, and RAD21 in tumor cells points to an activated cell cycle.
      • WEE1 is a kinase that inhibits CDK activity, allowing cells time for DNA repair before mitosis. Its overexpression in cancer can support tumor cell survival and proliferation by preventing premature mitotic entry under genomic stress, making it an attractive therapeutic target PubMed Search: WEE1 cancer proliferation.
      • E2F3 and its dimerization partner TFDP2 are transcription factors that activate genes involved in cell cycle progression and DNA synthesis. Their increased expression suggests a heightened drive for proliferation GeneCards: E2F3, GeneCards: TFDP2.
      • RAD21, a component of the cohesin complex, is crucial for sister chromatid cohesion during cell division, and its upregulation is consistent with active cell division GeneCards: RAD21.
    • YWHAB (14-3-3 beta), involved in cell cycle regulation, apoptosis, and signal transduction, is frequently overexpressed in various cancers and can promote proliferation, suggesting a role in the breast tumor context GeneCards: YWHAB.
    • CREBBP (CBP) is a histone acetyltransferase and transcriptional coactivator. While it has complex roles, its upregulation could contribute to altered transcriptional programs supporting tumor growth GeneCards: CREBBP.
  2. Dysregulation of Cell Cycle Inhibitors and Tumor Suppressors:
    • MDM2 is significantly upregulated in tumor cells. MDM2 is an E3 ubiquitin ligase that targets the tumor suppressor TP53 for degradation. Its overexpression typically leads to inactivation of TP53, thereby abrogating cell cycle arrest and apoptosis pathways that TP53 normally controls GeneCards: MDM2. This finding, in conjunction with the non-significant but slightly higher expression of TP53 in normal cells, strongly suggests a pathway for TP53 inactivation in primary tumors.
    • Intriguingly, tumor suppressors and cell cycle inhibitors like CDKN2D (p19INK4d), CDKN2A (p16INK4a/p14ARF), and CDKN1A (p21) show significantly *higher* expressing cell fractions in tumor cells. This might represent:
      • Compensatory mechanisms: The tumor cells are experiencing significant oncogenic stress, driving a compensatory upregulation of these inhibitors in an attempt to restrain uncontrolled proliferation.
      • Senescence-associated programs: Overexpression of p16 and p21 can be markers of cellular senescence, a stable cell cycle arrest. Some tumor cells may enter a senescent-like state in response to oncogenic signaling.
      • Context-specific roles: The roles of these genes can be complex and context-dependent. For example, specific mutations or loss of function in other pathways might lead to their upregulation as a secondary effect without restoring their tumor suppressive function.
    • GADD45G, a stress-inducible gene involved in DNA repair and cell cycle arrest, is upregulated in tumors, possibly reflecting increased DNA damage or genomic instability characteristic of cancer cells GeneCards: GADD45G.
    • CDKN1C (p57Kip2), another CDK inhibitor, is also upregulated. Its role in cancer is complex and can vary by tumor type GeneCards: CDKN1C.
  3. Specific Downregulation:
    • The downregulation of CCND3 (Cyclin D3) in tumor cells is less intuitive, as cyclins typically promote cell cycle progression. However, in breast cancer, other cyclins (e.g., CCND1) might be overexpressed and compensating, or this could indicate a specific subtype of breast cancer or a shift in specific cell cycle phases being driven GeneCards: CCND3.
    • E2F4 is often associated with repression of E2F target genes, promoting cell cycle arrest. Its downregulation in tumor cells could contribute to uncontrolled proliferation by releasing this repressive brake GeneCards: E2F4.

In summary, the epithelial cells within primary breast tumors exhibit a significantly altered landscape of cell cycle gene expression, characterized by the upregulation of numerous genes associated with proliferation, DNA damage response, and TP53 inactivation (MDM2), alongside complex, potentially compensatory, or context-dependent changes in tumor suppressors.

Clinical or Translational Implications

The widespread dysregulation of cell cycle pathway genes in primary breast tumor epithelial cells has several potential clinical and translational implications:

  1. Biomarker Potential: The identified genes with statistically significant differences in expressing cell fraction (e.g., YWHAB, WEE1, MDM2, E2F3, TFDP2) could serve as potential biomarkers for breast cancer diagnosis, prognosis, or monitoring treatment response. Their expression profiles might differentiate tumor from normal tissue and indicate proliferative activity.
  2. Therapeutic Targets:
    • WEE1 is a well-established target in cancer therapy, with inhibitors currently in clinical trials for various cancers. Its overexpression in breast tumor epithelial cells supports its investigation as a therapeutic target for breast cancer PubMed Search: WEE1 inhibitor breast cancer.
    • MDM2 overexpression, leading to TP53 inactivation, is another validated therapeutic target. MDM2 inhibitors aim to restore TP53 function and induce cell cycle arrest and apoptosis. This finding highlights the potential utility of MDM2 inhibitors in breast cancer PubMed Search: MDM2 inhibitor breast cancer.
    • The E2F pathway, including E2F3 and TFDP2, represents a core driver of proliferation, and its components could be explored as targets for anti-proliferative therapies.
  3. Understanding Treatment Resistance: The complex interplay of upregulated tumor suppressors (CDKN2A, CDKN2D, CDKN1A) in tumor cells, alongside oncogenic drivers, could shed light on mechanisms of intrinsic or acquired resistance to therapies. For instance, cells that upregulate these inhibitors might represent a subpopulation that is less susceptible to treatments targeting proliferation. Further research is needed to dissect the functional consequences of these seemingly contradictory expression patterns in the tumor context.

18. Gene Ontology (GSA) Analysis of Epithelial Cells in Breast Tissue Across Different Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Ontology (GSA) enrichment results for Epithelial cells, a cell type identified as the resolved tumor origin in the provided breast tissue single-cell RNA-seq dataset. The goal is to identify significantly enriched biological processes and pathways that are upregulated in Epithelial cells when comparing specific conditions against all other available conditions within the dataset. Three distinct comparisons were performed:

  1. Diploid_vs_others: Epithelial cells classified as Diploid compared to all other Epithelial cells.
  2. normal_vs_others: Epithelial cells from 'normal' tissue samples compared to all other Epithelial cells.
  3. primary_tumor_vs_others: Epithelial cells from 'primary_tumor' tissue samples compared to all other Epithelial cells.

The results are visualized as bar plots, showing the -log(p-val) and -log(q-val) for each enriched GO term, indicating the statistical significance of their upregulation.

Visual Summary

The bar plots display the top enriched Gene Ontology terms for Epithelial cells under each specified comparison. The length of the bars represents the statistical significance (-log(p-val) and -log(q-val)), with longer bars indicating higher significance.

Diploid Epithelial Cells (Diploid_vs_others)

Normal Epithelial Cells (normal_vs_others)

Primary Tumor Epithelial Cells (primary_tumor_vs_others)

Biological Interpretation

The Gene Ontology analysis highlights distinct biological activities within Epithelial cells under different conditions, providing insights into their functional states in the context of breast tissue and disease.

Diploid Epithelial Cells

The enrichment of numerous viral infection-related pathways in diploid epithelial cells is notable. While some viruses are directly oncogenic (e.g., HPV, EBV), their widespread presence in seemingly "diploid" cells might reflect latent infections, general antiviral responses, or subtle pro-tumorigenic alterations that occur early or are not yet associated with aneuploidy. The presence of "Focal adhesion" suggests active cell-matrix interactions, while "Ribosome" and "Spliceosome" indicate basic cellular machinery. The "Proteoglycans in cancer" and "Pathways in cancer" terms suggest that even diploid epithelial cells within a cancerous environment may exhibit features associated with neoplastic processes, potentially representing cells in a pre-malignant state or those influenced by the tumor microenvironment.

Normal Epithelial Cells

Normal epithelial cells predictably show strong enrichment for "Ribosome" and "Proteasome," underscoring their role in maintaining protein homeostasis through active synthesis and degradation. The consistent presence of "Focal adhesion" reflects the importance of cell-matrix integrity in healthy tissue. The enrichment of neurodegenerative pathways (e.g., "Parkinson disease," "Alzheimer disease") in breast epithelial cells is unexpected. This may indicate a broader cellular stress response, protein misfolding, or mitochondrial dysfunction that are common underlying mechanisms in various pathologies, not solely confined to neural tissues. It suggests general cellular maintenance challenges rather than direct neurodegeneration in breast cells.

Primary Tumor Epithelial Cells

The most striking findings are observed in primary tumor epithelial cells, where a clear signature of cancer hallmarks emerges:

In summary, normal epithelial cells focus on fundamental protein metabolism, while diploid cells within the tissue context show signs of viral interactions and early cancer-associated changes. Primary tumor epithelial cells, however, display a profound shift towards metabolic reprogramming, increased cellular stress, and activation of key growth-promoting signaling pathways, reflecting their highly proliferative and adaptive malignant state.

Clinical or Translational Implications

The distinct biological signatures observed in primary tumor epithelial cells offer several potential clinical and translational implications for breast cancer:

---

References:

[1] Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646-674. PubMed Search: "cancer metabolic reprogramming hallmarks"

[2] Lipton, L. R., et al. (2010). mTOR pathway inhibition in cancer therapy. British Journal of Cancer, 102(9), 1210–1215. PubMed Search: "mTOR signaling cancer"

[3] Gurevich, V. V., et al. (2020). G protein-coupled receptor kinase 2 (GRK2) in cancer: Emerging roles and therapeutic implications. Cancers, 12(9), 2419. PubMed Search: "MAPK signaling breast cancer"

[4] Xu, R., et al. (2020). Wnt signaling in breast cancer: molecular mechanisms and therapeutic strategies. Journal of Hematology & Oncology, 13(1), 101. PubMed Search: "Wnt signaling breast cancer"

[5] Yarden, Y., & Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology, 2(2), 127-137. PubMed Search: "ErbB signaling breast cancer"

19. Gene Set Enrichment Analysis (GSEA) Across Breast Tissue Cell Types in Primary Tumor vs. Normal Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Set Enrichment Analysis (GSEA) results visualized as a dot plot. The analysis compares gene expression profiles across various cell types found in breast tissue under different conditions. Specifically, for each celltype_minor, gene sets were compared between 'primary_tumor' and 'normal' conditions against 'others' (all other cells in the dataset not belonging to the specific cell type and condition being tested). An additional comparison for 'Epithelial cell' focused on 'Diploid' cells versus 'others'. The plot displays the Normalized Enrichment Score (NES) using a RdBu_r colormap (red indicating upregulation, blue indicating downregulation) and the statistical significance (-log(p-val)) as dot size. A total of 120 highly significant pathways are shown.

Visual Summary

The dot plot effectively illustrates distinct pathway enrichment patterns across different cell types and conditions.

Biological Interpretation

The GSEA results provide strong biological insights into the molecular landscape of breast cancer, highlighting both tumor-intrinsic mechanisms and critical interactions within the tumor microenvironment.

  1. Hallmarks of Cancer in Epithelial Cells:
    • Uncontrolled Proliferation and Metabolism: The significant upregulation of "Breast cancer", "Pathways in cancer", "PI3K-Akt signaling pathway" PubMed search: PI3K-Akt pathway cancer, "Wnt signaling pathway" GeneCards: WNT pathway, "DNA replication", "Ribosome", "RNA polymerase", and "mTOR signaling pathway" GeneCards: mTOR pathway in primary tumor epithelial cells is highly consistent with the known hallmarks of cancer, including sustained proliferative signaling, altered cellular metabolism (e.g., increased protein synthesis and nucleic acid metabolism), and resistance to cell death.
    • Extracellular Matrix Remodeling and Cell Adhesion: Upregulation of "ECM-receptor interaction" and "Focal adhesion" suggests active remodeling of the tumor microenvironment and altered cell-matrix interactions, critical for tumor invasion and metastasis.
    • Tumor Suppressor and Oncogene Dynamics: The upregulation of "p53 signaling pathway" in tumor epithelial cells is intriguing. While p53 is a tumor suppressor, its activation could indicate cellular stress responses in early tumorigenesis, or it might point to dysfunctional p53 pathways (e.g., gain-of-function mutations) commonly observed in cancer. "Signaling pathways regulating pluripotency of stem cells" also being enriched suggests a potential cancer stem cell phenotype, contributing to tumor recurrence and resistance.
    • Metabolic Reprogramming: The downregulation of "Oxidative phosphorylation" and "Fatty acid degradation" while anabolic processes are upregulated is indicative of the Warburg effect, where cancer cells shift towards aerobic glycolysis for energy, even in the presence of oxygen PubMed search: Warburg effect cancer.
  2. Tumor Microenvironment Engagement:
    • Angiogenesis: The "VEGF signaling pathway" GeneCards: VEGFA is significantly upregulated in Endothelial cells, Macrophages, and Smooth muscle cells within the primary tumor. This is a crucial finding, indicating active angiogenesis—the formation of new blood vessels—which is essential for tumor growth and metastasis.
    • Stromal Remodeling by CAFs: Fibroblasts in the tumor context show upregulation of "ECM-receptor interaction", "Focal adhesion", and "Regulation of actin cytoskeleton", consistent with their activation into Cancer-Associated Fibroblasts (CAFs). CAFs play a pivotal role in ECM remodeling, promoting tumor invasion and metastasis.
    • Immune Cell Reprogramming: Macrophages in the primary tumor microenvironment show upregulation of pathways associated with pro-tumoral functions, such as "VEGF signaling pathway" and "Wnt signaling pathway", indicating their potential polarization towards a tumor-associated macrophage (TAM) phenotype that supports tumor growth, angiogenesis, and immune evasion.
    • Shared Metabolic Shifts: The downregulation of "Oxidative phosphorylation" and "Fatty acid degradation" across various TME cell types (Endothelial cells, Fibroblasts, Macrophages, Smooth muscle cells) suggests a broader metabolic reprogramming not limited to tumor cells but extending to the supporting stromal cells, potentially creating a unique metabolic niche that favors tumor survival.
  3. Diploid Epithelial Cells vs. Tumor Epithelial Cells:
    • The "Epithelial cell: Diploid_vs_others" comparison largely mirrors the "normal_vs_others" pattern, with "Breast cancer" and other oncogenic pathways being downregulated, while some homeostatic pathways are relatively enriched. This highlights the distinct molecular phenotype of diploid epithelial cells, which are likely healthy or non-transformed, compared to the aneuploid and primary tumor epithelial cells.

Clinical or Translational Implications

The GSEA results provide a robust molecular signature of breast cancer progression and interaction with its microenvironment, offering several potential clinical and translational implications:

20. Discussion

This single-cell analysis of breast tissue provides a detailed characterization of breast cancer, identifying significant shifts in cellular composition, genomic stability, intercellular communication, and metabolic programming within the tumor microenvironment (TME). Tumor-origin epithelial cells are definitively identified by their aneuploid status and distinct transcriptional profiles, which segregate sharply from normal epithelial cells. Recurrent copy number amplifications, notably affecting regions harboring EGFR, MYC (on 8q), and CCND1 (on 11q), are prevalent in these malignant epithelial cells, highlighting key genomic drivers of tumorigenesis. The CNV-informed UMAPs further reveal considerable intra-tumor genomic heterogeneity among aneuploid cell populations.

The TME undergoes profound remodeling, marked by altered cellular proportions and phenotypes. Primary tumors exhibit increased infiltration of fibroblasts (often becoming cancer-associated fibroblasts, or CAFs) and macrophages, which polarize towards pro-tumorigenic M2-like phenotypes. While an increase in cytotoxic T cells suggests an anti-tumor immune response, there is also a significant expansion of immunosuppressive regulatory T cells (Tregs) and pro-tumorigenic Th17, Th9, and Th2 helper T cell subsets, alongside a reduction in lymphoid tissue inducer (LTI) cells. This indicates a complex immune landscape characterized by both active response and active immune evasion. A notable 'unassigned' cell population specifically enriched in tumors suggests the presence of novel or highly plastic cell states within the malignant context.

Cell-cell interaction (CCI) analyses reveal a dramatic upregulation and diversification of communication networks in the primary tumor. Normal tissue interactions are dominated by extracellular matrix (ECM) maintenance. In contrast, tumor CCIs involve extensive crosstalk between malignant epithelial cells, CAFs, tumor-associated macrophages (TAMs), and endothelial cells. Key upregulated interactions include SPP1-CD44 (promoting tumor progression), VEGFA-NRP1/FLT1 (driving angiogenesis), CXCL12-CXCR4 (facilitating migration and recruitment), and GAS6-AXL (enhancing cell survival and drug resistance). The TGF-beta signaling pathway, particularly involving TGFB1-integrin_avB6_complex, is also highly activated and diversified across the TME, promoting tumor growth, immune evasion, and fibrosis. ECM-integrin interactions are broadly dysregulated, contributing to a stiff, pro-invasive TME.

At the molecular level, tumor epithelial cells exhibit severe dysregulation of cell cycle machinery, with upregulation of proliferation-promoting genes (e.g., WEE1, E2F3, TFDP2, RAD21) and MDM2 (a negative regulator of TP53), indicative of uncontrolled cell division and impaired tumor suppression. Intriguingly, some cell cycle inhibitors like CDKN2D, CDKN2A, and CDKN1A are also upregulated, potentially reflecting compensatory stress responses or context-dependent roles. Gene Ontology (GSA) and Gene Set Enrichment Analysis (GSEA) reveal a widespread metabolic reprogramming towards increased thermogenesis, oxidative phosphorylation, protein processing, and activation of central growth-promoting pathways such as mTOR, PI3K-Akt, MAPK, Wnt, and ErbB signaling across tumor epithelial cells and supporting stromal components, characteristic of the Warburg effect. Unexpectedly, GSA in diploid epithelial cells also indicates an enrichment of viral infection pathways, warranting further investigation into early cellular alterations. The coordinated changes in genomic stability, TME composition, intercellular communication, and cellular metabolism collectively define the aggressive phenotype of breast cancer and offer multiple vulnerabilities for therapeutic targeting.

Hypotheses:

  1. The observed metabolic reprogramming, including reliance on oxidative phosphorylation and altered lipid metabolism in primary tumor epithelial cells and associated stromal cells, is critical for sustaining tumor growth and immune evasion, making these pathways viable therapeutic targets.
  2. The distinct pro-tumorigenic shifts in T cell (Th17, Th9, Th2 enrichment, LTI reduction) and macrophage (M2-like polarization) populations actively contribute to immune suppression, and targeting these immune cell phenotypes could re-sensitize breast tumors to immunotherapy.
  3. The highly active cell-cell interaction networks, particularly involving CAFs, TAMs, and tumor epithelial cells (e.g., TGF-beta, SPP1-CD44, CXCL12-CXCR4, GAS6-AXL, integrin-ECM), are essential for breast cancer progression and metastasis, and their inhibition could halt disease dissemination.
  4. Specific recurrent copy number amplifications (e.g., EGFR, MYC/8q, CCND1/11q) identified in aneuploid epithelial cells drive tumor growth and represent intrinsic vulnerabilities that could be targeted to directly reduce tumor cell proliferation.
  5. The 'unassigned' cell population prominently observed in primary tumors represents novel, highly plastic, or dedifferentiated malignant cells that contribute to tumor heterogeneity and may possess unique resistance mechanisms.

Potential therapeutic targets:

  1. ERBB2 (HER2): An oncogenic receptor tyrosine kinase that drives cell proliferation, survival, and differentiation. Its overexpression defines a major subtype of aggressive breast cancer. Evidence: High and prominent expression in primary tumor epithelial cells, but not normal epithelial cells (Section 14). Validation: Immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) on breast tumor biopsies to confirm protein overexpression or gene amplification, followed by assessing patient response to HER2-targeted therapies.
  2. EGFR: A receptor tyrosine kinase whose signaling promotes cell growth, proliferation, migration, and angiogenesis. Its overexpression or amplification is a driver in various cancers. Evidence: Higher expression in primary tumor epithelial cells (Section 14). Amplification of the EGFR locus (7p12.2:7q21.11) was recurrently observed in tumor-origin epithelial cells (Section 4). Validation: IHC/FISH on tumor biopsies to confirm overexpression/amplification, and preclinical/clinical evaluation of EGFR inhibitors in breast cancer subtypes exhibiting high EGFR activity.
  3. MET: The MET proto-oncogene encodes a receptor tyrosine kinase. Aberrant MET activation drives tumor growth, invasion, and metastasis in several cancers by promoting cell proliferation, survival, and migration. Evidence: Upregulated expression in primary tumor epithelial cells (Section 14) and primary tumor macrophages (Section 15). Validation: IHC to assess MET protein levels in tumor cells and TAMs, followed by preclinical testing of MET inhibitors in breast cancer models, potentially exploring dual targeting of tumor cells and TAMs.
  4. NECTIN4: A cell adhesion molecule overexpressed in various cancers, promoting cell proliferation and migration. It is an excellent target for antibody-drug conjugates (ADCs) due to its cell surface localization. Evidence: High and selective expression in primary tumor epithelial cells compared to normal epithelial cells (Section 14). Validation: IHC to confirm NECTIN4 expression in diverse breast cancer subtypes, followed by preclinical and clinical trials of NECTIN4-targeting ADCs (e.g., enfortumab vedotin in relevant contexts).
  5. MUC1: A transmembrane glycoprotein frequently overexpressed and aberrantly glycosylated in breast cancer, playing roles in cell signaling, adhesion, and immune evasion. It is a target for immunotherapy and antibody-based therapies. Evidence: High expression in primary tumor epithelial cells (Section 14). Validation: IHC to confirm MUC1 expression, followed by preclinical testing of MUC1-targeting antibodies or immunotherapies, particularly in triple-negative breast cancer (TNBC) models.
  6. CD44: A cell surface glycoprotein associated with cancer stem cell properties, cell adhesion, migration, and metastasis. Its interaction with SPP1 can promote tumor progression and immune evasion. Evidence: Highly expressed in primary tumor epithelial cells (Section 14). Strong SPP1-CD44 interactions observed between macrophages and aneuploid epithelial cells in primary tumors (Section 11). Validation: Functional assays targeting CD44 (e.g., with specific antibodies or small molecule inhibitors) in models of tumor recurrence and metastasis, potentially in combination with SPP1 inhibitors.
  7. FOLR1: Folate receptor alpha (FOLR1) is overexpressed in various cancers, including breast cancer, and is involved in cell growth. It serves as a target for folate-drug conjugates. Evidence: Expression detected in breast tumor epithelial cells (Section 14). Validation: IHC to confirm FOLR1 expression in breast cancer tissues, followed by preclinical studies evaluating the efficacy of FOLR1-targeting folate-drug conjugates.
  8. IL6R (CD126) on Macrophages: IL6R binds IL-6, activating the JAK-STAT3 pathway in tumor-associated macrophages (TAMs), promoting their pro-tumorigenic M2-like phenotype, angiogenesis, and immune suppression. Evidence: Upregulated expression in primary tumor macrophages (Section 15). Validation: Functional assays using anti-IL-6R antibodies (e.g., tocilizumab) to reprogram TAMs towards an anti-tumor phenotype or inhibit their pro-tumor functions in breast cancer models.
  9. CXCR4 on Macrophages (CXCL12-CXCR4 axis): CXCR4, when bound by CXCL12, recruits macrophages to the tumor site and promotes TAM survival, differentiation, and pro-tumorigenic functions, including angiogenesis and metastasis. Evidence: Upregulated expression in primary tumor macrophages (Section 15). Strong CXCL12-CXCR4 interactions observed between fibroblasts and endothelial cells in primary tumors (Section 13) and in overall tumor CCI (Section 11). Validation: Functional assays using CXCR4 antagonists (e.g., Plerixafor) to inhibit TAM recruitment, reduce metastatic dissemination, and modulate the immune TME in breast cancer models.
  10. ITGAV (CD51) / ITGB2 (CD18) Integrins on Macrophages: These integrin subunits form heterodimers critical for TAM adhesion, migration, and interaction with the ECM and tumor cells, facilitating TAM recruitment, retention, and pro-tumorigenic functions. Evidence: Upregulated expression of ITGAV and ITGB2 in primary tumor macrophages (Section 15). Validation: Blocking specific integrins (e.g., using antibodies targeting relevant heterodimers containing ITGAV or ITGB2) to impede TAM infiltration into tumors and inhibit their pro-tumor functions in preclinical models.
  11. FAP (Fibroblast Activation Protein alpha) on Fibroblasts: A hallmark of activated cancer-associated fibroblasts (CAFs) that promotes tumor growth, invasion, metastasis, and angiogenesis, while also fostering an immunosuppressive TME. Minimally expressed in normal adult tissues. Evidence: Highly expressed and prevalent in primary tumor fibroblasts (Section 16). Validation: Preclinical and clinical testing of FAP-targeted strategies, including monoclonal antibodies, small molecule inhibitors, FAP-targeted CAR-T cell therapies, or FAP-targeted radionuclide therapies, to disrupt CAF functions.
  12. MMP14 (Matrix Metallopeptidase 14) on Fibroblasts: A membrane-anchored matrix metalloproteinase that directly degrades ECM components and activates other MMPs, driving ECM remodeling, tumor cell invasion, metastasis, and angiogenesis. Evidence: Highly expressed and prevalent in primary tumor fibroblasts (Section 16). Validation: Preclinical investigation of specific MMP14 inhibitors to disrupt ECM degradation, tumor invasion, and metastatic dissemination in breast cancer models.
  13. AXL Receptor Tyrosine Kinase on Fibroblasts: Activated by GAS6, AXL drives cell proliferation, survival, migration, and drug resistance. Overexpressed in aggressive cancers and often in CAFs, promoting tumor progression, metastasis, and immune evasion. Evidence: Highly expressed and prevalent in primary tumor fibroblasts (Section 16). GAS6-AXL interactions also observed in tumor context involving fibroblasts and endothelial cells (Section 13). Validation: Clinical trials of AXL inhibitors (e.g., bemcentinib, cabozantinib) to overcome resistance to existing therapies, reduce metastasis, and modulate the immune TME in breast cancer.
  14. NRP1 (Neuropilin 1) on Fibroblasts: A co-receptor for VEGF-A and other ligands, NRP1 enhances pro-angiogenic signaling, promotes tumor angiogenesis, growth, and metastasis. In CAFs, it contributes to immune suppression and mediates TME interactions. Evidence: Highly expressed in primary tumor fibroblasts (Section 16). VEGFA-NRP1 interactions observed in tumor context involving endothelial cells, macrophages, smooth muscle cells (Sections 11, 13, 19). Validation: Preclinical testing of NRP1-targeting antibodies to block its ability to promote angiogenesis and tumor progression, potentially in combination with anti-VEGF therapies.
  15. GPNMB (Glycoprotein NMB) on Fibroblasts: A transmembrane glycoprotein associated with aggressive tumor phenotypes, metastasis, and therapy resistance. It promotes cell adhesion, motility, and proliferation. Promising for targeted drug delivery. Evidence: Highly expressed in primary tumor fibroblasts (Section 16). Validation: Preclinical testing of GPNMB-targeting antibody-drug conjugates (ADCs) in breast cancer models, especially in aggressive subtypes like TNBC.
  16. CDH11 (Cadherin 11) on Fibroblasts: A classical cadherin upregulated in CAFs that promotes CAF activation, collective cell migration, and enhances tumor cell invasion and metastasis by facilitating critical tumor-stroma interactions. Evidence: Upregulated in primary tumor fibroblasts (Section 16). Validation: Preclinical investigation of monoclonal antibodies targeting CDH11 to disrupt CAF-tumor cell interactions and inhibit metastatic processes in breast cancer models.
  17. ANTXR1 (Anthrax Toxin Receptor 1) on Fibroblasts: Highly expressed in tumor vasculature and some stromal cells, promoting tumor angiogenesis and growth. Considered a tumor endothelial marker and target for targeted drug delivery to the TME. Evidence: Highly expressed in primary tumor fibroblasts (Section 16). Validation: Preclinical testing of ANTXR1-targeting ADCs or immunotoxins to specifically deliver cytotoxic agents to tumor blood vessels and CAFs.
  18. CD276 (B7-H3) on Fibroblasts: An immune checkpoint molecule highly expressed on tumor cells and CAFs, acting as an immune suppressor and promoting immune evasion. Offers potential for immune checkpoint inhibition or ADCs. Evidence: Highly expressed in primary tumor fibroblasts (Section 16). Validation: Clinical trials evaluating anti-B7-H3 therapies (e.g., ADCs or checkpoint inhibitors) to overcome immune suppression in the breast cancer TME.
  19. WEE1 Kinase (in Epithelial cells): A kinase that inhibits CDK activity, allowing cells time for DNA repair before mitosis. Its overexpression in cancer can support tumor cell survival and proliferation under genomic stress. Evidence: Significantly higher expressing cell fraction in primary tumor epithelial cells compared to normal (Section 17). Validation: Clinical trials of WEE1 inhibitors (e.g., adavosertib) in breast cancer, potentially in combination with DNA-damaging chemotherapies, to exploit its role in managing oncogenic stress.
  20. MDM2 (in Epithelial cells): An E3 ubiquitin ligase that targets the tumor suppressor TP53 for degradation. Its overexpression leads to inactivation of TP53, abrogating cell cycle arrest and apoptosis pathways. Evidence: Significantly higher expressing cell fraction in primary tumor epithelial cells compared to normal (Section 17). Validation: Clinical trials of MDM2 inhibitors (e.g., idasanutlin) to restore TP53 function, induce cell cycle arrest, and apoptosis in breast cancer, particularly in TP53 wild-type tumors.
  21. TGF-beta Pathway: A pleiotropic cytokine pathway that, in advanced cancer, promotes tumor progression, immune evasion, angiogenesis, and metastasis. Activated extensively across tumor epithelial cells, fibroblasts, and macrophages. Evidence: Strong and diversified TGFB1/2-TGFbeta_receptor signaling, especially TGFB1-integrin_avB6_complex, observed between tumor epithelial cells, fibroblasts, and macrophages in primary tumors (Section 12). Validation: Clinical trials of TGF-beta inhibitors (e.g., TGF-beta receptor inhibitors, ligand traps, or integrin αvβ6 inhibitors) to block its pro-tumorigenic effects and immune suppression in breast cancer.
  22. PI3K-Akt Signaling Pathway: A central pathway regulating cell proliferation, survival, growth, and metabolism. Frequently hyperactivated in breast cancer and its microenvironment. Evidence: Upregulated in primary tumor epithelial cells, endothelial cells, fibroblasts, macrophages, and smooth muscle cells in GSEA analysis (Section 19). Validation: Clinical trials of PI3K, Akt, or mTOR inhibitors (e.g., alpelisib, capivasertib, everolimus) in breast cancer, potentially in combination to overcome resistance or target multiple cell types.
  23. mTOR Signaling Pathway: A key regulator of cell growth, proliferation, and metabolism. Its hyperactivation contributes to many cancer hallmarks. Evidence: Highly enriched/upregulated in primary tumor epithelial cells, endothelial cells, fibroblasts, macrophages, and smooth muscle cells in GSA and GSEA analyses (Sections 18, 19). Validation: Clinical trials of mTOR inhibitors (e.g., everolimus, sirolimus) in breast cancer, alone or in combination, focusing on patient subsets with high mTOR pathway activity.

Follow-up validation ideas:

  1. Flow cytometry / Immunostaining / Spatial Transcriptomics: Validate the presence and spatial localization of altered T cell subsets (e.g., Th17, Treg, LTI), macrophage subsets (M1/M2-like), and CAFs (e.g., FAP+, AXL+, MMP14+) and their spatial relationships within human breast tumor samples. This can confirm the cellular composition changes and interactions identified.
  2. Perturbation Assays (in vitro/in vivo): Using patient-derived organoids, cell lines, or xenograft models, test the functional impact of inhibiting key signaling pathways (e.g., PI3K-Akt, Wnt, mTOR, VEGF, TGF-beta, AXL, FAP, MMP14, WEE1, MDM2) on tumor cell proliferation, survival, invasion, and immune evasion. This involves specific inhibitors or genetic knockdowns/knockouts.
  3. Ligand-Receptor Blocking Studies: Employ blocking antibodies or small molecule inhibitors for critical cell-cell interaction pairs (e.g., SPP1-CD44, CXCL12-CXCR4, VEGFA-NRP1, TGFB1-integrin_avB6_complex) in co-culture systems or *in vivo* models to assess their impact on tumor cell invasion, angiogenesis, and immune cell recruitment.
  4. Metabolic Tracing / Metabolomics: Confirm and characterize the specific metabolic reprogramming pathways (e.g., Warburg effect, altered lipid metabolism) identified by GSEA/GSA in tumor epithelial cells and CAFs/TAMs, using isotope tracing or targeted metabolomics on patient samples or cell lines.
  5. CNV-FISH / qPCR / Genomic Sequencing: Orthogonally validate specific recurrent copy number amplifications (e.g., EGFR, MYC, CCND1) in aneuploid epithelial cells from patient tumor samples at the DNA level and correlate with protein expression and clinical outcomes.
  6. Bulk / Single-cell Validation Cohorts: Analyze larger cohorts of breast cancer patients using bulk RNA-seq, proteomics, or single-cell techniques to validate the identified cell type population shifts, marker expression profiles, and pathway activities as prognostic or predictive biomarkers.
  7. Functional Characterization of 'Unassigned' Cells: Isolate or computationally deconvolve the 'unassigned' cell population and perform deeper multi-omics (e.g., ATAC-seq, CITE-seq) and functional assays to characterize their unique properties, differentiation potential, and contribution to tumor progression or therapy resistance.

Limitations:

This single-cell RNA sequencing analysis provides a snapshot of the tumor microenvironment and cellular states, inherently limiting causal inferences. While specific gene expression changes and cell-cell interactions are identified, functional validation is required to establish direct causality. The observed patient heterogeneity, particularly within primary tumor samples, indicates that findings may not generalize universally across all breast cancer patients. The presence of an 'unassigned' cell population highlights potential limitations in current cell type annotation references or the existence of novel, uncharacterized cell states. Inferences of protein function from RNA expression assume direct correlation, which may not always hold true due to post-transcriptional regulation. Future studies incorporating spatial transcriptomics and multi-modal analyses would enhance the understanding of cellular context and direct molecular interactions.

21. Query List

  1. Show and save UMAPs for condition, sample, major cell type, minor cell type, ploidy_dec, and celltype_subset in two columns.
  2. Show major cell type scores on UMAP and save the result.
  3. Show and save a marker expression dot plot for celltype_subset. SET target_cell = None and var_group_rotation = 45. Leave all other arguments at their default values.
  4. Select Epithelial cell tumor-origin cells, show a CNV heatmap grouped by sample together with a summary of regions with significantly amplified copy numbers, and save the results.
  5. Show and save UMAPs of CNV patterns colored by major cell type, minor cell type, ploidy results, condition, and sample in two columns.
  6. Show and save a population bar plot of minor cell types.
  7. Show and save a population bar plot of T cell subsets.
  8. Show and save box plots of T cell subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
  9. Show and save a population bar plot of macrophage subsets.
  10. Select Epithelial cell tumor-origin cells, show their ploidy populations as a bar plot, and save the result.
  11. Show and save cell-cell interaction patterns involving Epithelial cells, Fibroblast, Macrophage, T cell, and other relevant cell types. Select at most 80 cell-cell interactions per group.
  12. Select only genes associated with immune checkpoint and cell cycle pathways, show cell-cell interactions for these genes, and save the result.
  13. Find cell-cell interactions involving major immune and stromal cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60. For each interaction identified under each condition, using the provided dataset context, describe the associated signaling pathways and mechanisms, its potential as a therapeutic target, and relevant therapeutic agents.
  14. Show marker expressions for Epithelial cells in a dot plot, and save the result. Use only surfaceome markers, with at most 60 markers per condition. For the markers identified under each condition, distinguish between established therapeutic targets and less well-characterized markers with potential as therapeutic targets. For each marker, using the provided dataset context, describe the associated signaling pathways and mechanisms, relevant therapeutic agents, and supporting evidence.
  15. Show marker expressions for Macrophage in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information.
  16. Show marker expressions for Fibroblast in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information.
  17. Among cell cycle pathway genes, select those with statistically significant expression differences between conditions in Epithelial cells, show box plots, and save the result. Set max_n_items_to_plot to 24 and choose ncols based on the total number of panels for an overall width-to-height ratio of approximately 2:3.
  18. Show and save Gene Ontology (GSA) analysis results for Epithelial cells as a bar plot.
  19. Show Gene Set Enrichment Analysis results as a dot plot, and save it. Set the color map to RdBu_r, n_pws_to_show to 120, and target_cells to None.
Top